Health Care • Medical/Dental Instruments
$229.94 ▼ -22.89
(-9.05%)
MKT CAP: $35.56B • VOL: 3.47M
52W L $180 52W H $278
RMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $5.15B | $4.69B | $4.22B |
| YoY Revenue Growth % | +9.8% | +10.9% | — |
| Gross Profit | $3.05B | $2.66B | — |
| Gross Margin % | 59.4% | 56.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.69B | $1.32B | $1.13B |
| Operating Margin % | 32.7% | 28.2% | 26.8% |
| Net Income (GAAP) | $1.40B | $1.02B | $898.0M |
| EBITDA (Normalized) | $1.76B | $1.40B | $1.28B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.75B | $1.40B | $693.3M |
| Capital Expenditures (CapEx) | $89.9M | $99.5M | $190.0M |
| Free Cash Flow (FCF) | $1.66B | $1.30B | $503.3M |
| FCF Margin % | 32.3% | 27.8% | 11.9% |
| Return on Invested Capital (ROIC %) | 22.6% | 18.7% | 7.6% |
| Cash & Short-Term Equivalents | $1.42B | $521.9M | — |
| Total Debt (Short + Long Term) | $982.1M | $849.7M | $4.58B |
| Total Stockholders' Equity | $6.32B | $5.25B | $9.39B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RMD.